19 August 2022 | News
The new centre of Trivitron will have provision to manufacture 300 million RT-PCR tests and over 70 million tests of Rapid Card/POCT per annum
Trivitron Healthcare has launched a centre of excellence with state-of-the-art R&D and manufacturing facilities at AMTZ Campus, Vishakhapatnam. The launch ceremony was attended by Prof Ajay Kumar Sood, Principal Scientific Advisor to the Government of India and Prof (Dr) Balram Bhargava, Former Director General, Indian Council of Medical Research.
Dr GSK Velu, Chairman & Managing Director, Trivitron Healthcare said: "This centre will implement research and innovation in the field of Metabolomics, Genomics, Newborn Screening, and Molecular Diagnostics and bring out cost-effective and affordable medical technology products and services."
The centre includes an Advanced Genomics and Molecular diagnostics facility for developing kits and reagents for Next Generation Sequencing (NGS) and Oligonucleotide synthesis (synthesis of customized primers and Taq Man Chemistry dual labelled probes), Protein Chemistry (design and expression of different recombinant enzymes and proteins), Cell culture and analytical lab. The company plans to manufacture all the raw materials and components of molecular diagnostics, NBS, and NGS in-house following advanced protocols and research approaches.
The new centre of Trivitron will have provision to manufacture 300 million RT-PCR tests and over 70 million tests of Rapid Card/POCT per annum. Additionally, more than 100 million tests can be manufactured for Genomics, ELISA, CLIA, NBS and other diagnostics kits.